Importance of quality of life in patients with non-small-cell lung cancer

Clinical Lung Cancer

Volumn 10, Issue 2, 2009, Pages 83-90

  Camps, Carlos ^a,b   Del Pozo, Nieves ^a   Blasco, Ana ^a   Blasco, Pilar ^a   Sirera, Rafael ^a,b  

^a HOSPITAL GENERAL UNIVERSITARIO DE VALENCIA   (Spain)

^b Hospital General Universitario   (Spain)

Author keywords

Clinical trial; Evaluation instrumentation; Measurement index; Palliative therapy

Indexed keywords

CARBOPLATIN; CISPLATIN; DOCETAXEL; EPIRUBICIN; GEFITINIB; GEMCITABINE; IFOSFAMIDE; MITOMYCIN C; NAVELBINE; PACLITAXEL; VINBLASTINE;

ARTICLE; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER PATIENT; CANCER SURVIVAL; CLINICAL EXAMINATION; CLINICAL PRACTICE; CLINICAL TRIAL; DECISION MAKING; HUMAN; LUNG CANCER; LUNG NON SMALL CELL CANCER; MULTIPLE CYCLE TREATMENT; PERFORMANCE; PROGNOSIS; QUALITY OF LIFE; QUESTIONNAIRE; SCORING SYSTEM; TREATMENT OUTCOME; TREATMENT PLANNING;

EID: 65349117548     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2009.n.010     Document Type: Review

References (47)

1. Rodríguez Sánchez, César A. In favour of the evaluation of the QoL in research. Clin Transl Oncol Suppl; 2007:97-8.
2. Bottomley A. The cancer patient and quality of life. Oncologist 2002; 7:120-5.
3. Aaronson NK, Ahmedzai S, Bergman B, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: A quality of life instrument for use in international clinical trials in oncology. J Natl Cancer Inst 1993; 85:365-76.
4. Carlson JJ, Reyes C, Oestreicher N, et al. Comparative clinical and economic outcomes of treatments for refractory non-small cell lung cancer (NSCLC). Lung Cancer 2008; 61:405-15.
5. Silvestri G, Pritchard R, Welch HG. Preferences for chemotherapy in patients with advanced non-small cell lung cancer: descriptive study based on scripted interviews. BMJ 1998; 317:771-5.
6. Cella D F, Patel JD. Improving health-related quality of life in non-small-cell lung cancer with current treatment options. Clin Lung Cancer 2008; 9:206-12.
7. Introduction. In: Fayers P, Machin D, eds. Quality of Life: Assessment, Analysis and Interpretation. Baffins Lane: Wiley; 2000:1-26.
8. Karnofsky, DA, Burcherval JH. The clinical evaluation of chemotherapeutic agents in cancer. In: MacLeod CM, ed. Evaluation of Chemotherapeutic Agents in Cancer. New York: Columbia University Press; 1949:191-205.
9. Yates JW, Chalmer B, McKegney F P. Evaluation of patient with advanced cancer using the Karnofsky Performance Status. Cancer 1980; 45:2220-4.
10. Mor V, Laliberte L, Morris JN, et al. The Karnofsky performance status scale: An examination of its reliability and validity in a research setting. Cancer 1984; 53:2002-7.
11. Casas J, Repullo JR, Pereira J. Measurements of quality of life in relation to health: Basic concepts, construction, and cultural adaption. Med Clin (Barc) 2001; 16:789-96.
12. Bergman B, Aaronson NK, Ahmedzai S, et al, for the EORTC Study Group on Quality of Life: The EORTC QLQLC13: A modular supplement to the EORTC Core Quality of Life Questionnaire (QLQ-C30) for use in lung cancer clinical trials. Eur J Cancer 1994; 30:635-42.
13. Osoba D, Rodrigues G, Myles J, et al. Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol 1998; 16:139-44.
14. Sarna L, Riedinger MS. Assessment of quality of life and symptom improvement in lung cancer clinical trials. Semin Oncol 2004; 31(suppl 9):1-10.
15. Cella D F. The Functional Assessment of Cancer Therapy - Lung and Lung Cancer Subscale assess quality of life and meaningful symptom improvement in lung cancer. Semin Oncol 2004; 31(suppl 9):11-5.
16. Cella D, Eton DT, Fairclough DL, et al. What is a clinically meaningful change on the Functional Assessment of Cancer Therapy - Lung (FACT-L) questionnaire? Results from Eastern Cooperative Oncology Group (ECOG) Study 5592. J Clin Epidemiol 2002; 55:285-95.
17. Cella D F, Bonomi AE, Lloyd SR, et al. Reliability and validity of the Functional Assessment of Cancer Therapy - Lung (FACT-L) quality of life instrument. Lung Cancer 1995; 12:199-220.
18. Stanley KE. Prognostic factors for survival in patients with inoperable lung cancer. J Natl Cancer Inst 1980; 65:25-32.
19. Jiroutek M, Johnson D, Blum R, et al. Prognostic factors in advanced non-small cell lung cancer (NSCLC): Analysis of Eastern Cooperative Oncology Group (ECOG) trials from 1981-1992. Proc Am Soc Clin Oncol 1998; 17:461.
20. Albain KS, Crowley JJ, LeBlanc M, et al. Survival determinants in extensive-stage non - small-cell lung cancer: The Southwest Oncology Group experience. J Clin Oncol 1991; 9:1618-26.
21. Maione P, Perrone F, Gallo C, et al. Pretreatment quality of life and functional status assessment significantly predict survival of elderly patients with advanced non-small-cell lung cancer receiving chemotherapy: a prognostic analysis of the multicenter Italian lung cancer in the elderly study. J Clin Oncol 2005; 23:6865-72.
22. Gralla RJ, Hollen PJ, Eberley S, et al. Quality of life score predicts response and survival in patients receiving chemotherapy for non-small cell lung cancer. Support Care Cancer 1995; 3:378-9.
23. Hollen PJ, Gralla RJ, Kris MG. Measurement of quality of life in patients with lung cancer in multicentre trial of new therapies: psychometrics assessment of the Lung Cancer Symptom Scale. Cancer 1994; 73:2087-98.
24. Herndon JE, Fleishman S, Kornblith AB, et al. Is quality of life predictive of the survival of patients with advanced non-small cell lung carcinoma? Cancer 1999; 85:333-40.
25. Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide and cisplatin in unresectable non-small cell lungcancer: effects on survival and quality of life. J Clin Oncol 1999; 17:3188-94.
26. Elderly Lung Cancer Vinorelbine Italian Study Group. Effects of Vinorelbine on quality of life and survival of elderly patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 1999; 91:66-72.
27. Thongprasert S, Sanguanmitra P, Juthapan W, et al. Relationship between quality of life and clinical outcomes in advanced non-small cell lung cancer: best supportive care (BSC) versus BSC plus chemotherapy. Lung Cancer 1999; 24:17-24.
28. Anderson H, Hopwood P, Stephens RJ. Gemcitabine plus best supportive care (BSC) versus BSC in inoperable non-small-cell lung cancer-a randomized trial with quality of life as the primary outcome. Br J Cancer 2000; 83:447-53.
29. Ranson M, Davidson N, Nicolson M, et al. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer. J Natl Cancer Inst 2000; 92:1074-80.
30. Roszkowski K, Pluzanska A, Krzakowski M, et al. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC). Lung Cancer 2000; 27:145-57.
31. Shepherd FA, Dancey J, Ramlau R, et al. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 2000; 18:2095-103.
32. Crinò L, Scagliotti GV, Ricci S, et al. Gemcitabine and cisplatin versus mitomycin, ifosfamide, and cisplatin in advanced non-small-cell lung cancer: a randomized phase III study of the Italian Lung Cancer Project. J Clin Oncol 1999; 17:3522-30.
33. Giaccone G, Splinter TA, Debruyne C, et al. Randomized study of paclitaxel - cisplatin versus cisplatin - etoposide in patients with advanced non-small-cell lung cancer. J Clin Oncol 1998; 16:2133-41.
34. Fossella F, Pereira JR, von Pawel J, et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: the TAX 326 study group. J Clin Oncol 2003; 21:3016-24.
35. Fossella F V, Lynch T, Shepherd FA. Second line chemotherapy for NSCLC: establishing a gold standard. Lung Cancer 2002; 38:5-12.
36. Rosell R, Gatzemeier U, Betticher DC, et al. Phase III randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer: a cooperative multinational trial. Ann Oncol 2002; 13:1539-49.
37. Smit E F, van Meerbeeck JPAM, Lianes P, et al. Three arm randomized study of two cisplatin-based regimens and paclitaxel plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the European Organization for Research and Treatment of Cancer Lung Cancer Group-EORTC 08975. J Clin Oncol 2003; 21:3909-17.
38. Gridelli C, Gallo C, Shepherd FA, et al. Gemcitabine plus vinorelbine compared with cisplatin plus vinorelbine or cisplatin plus gemcitabine in advanced non-small cell lung cancer: a phase III trial of the Italian GEMVIN Investigators and the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2003; 21:3025-34.
39. Georgoulias V, Ardavanis A, Tsiafaki X, et al. Vinorelbine plus cisplatin versus docetaxel plus gemcitabine in advanced non-small-cell lung cancer: a phase III randomized trial. J Clin Oncol 2005; 23:2937-45.
40. Bezjak A, Dongsheng T, Lesley S, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Trials Group Study BR.21. J Clin Oncol 2006; 24:3831-7.
41. Douillard J-Y, Skarin AT, Baselga J, et al. Improvement in disease-related symptoms and quality of life in patients with advanced non-small-cell lung cancer treated with ZD1839 ('Iressa') in IDEAL 1 and IDEAL 2. Presented at: the 2002 meeting of the European Society for Medical Onclogy; October 18-22, 2002; Nice, France. Abstract 480.
42. Thatcher N, Chang A, Parikh P, et al. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 2005; 366:1527-37.
43. Virinzuela Echaburu JA. En contra de la evaluación de la calidad de vida en la asistencia. XI Congreso SEOM. Clin Transl Oncol 2007; 99-100
44. Kuruvilla PG, Krieger H, Zibdawi L, et al. Assessing Quality of Life (QL) and Patient Reported Outcomes (PROs) in Clinical Trials and Clinical Practice: A Study Using a Hand-Held Computerized Form of the Validated LCSS Instrument in Patients with Non-Small Cell Lung Cancer (NSCLC). J Clin Oncol 2005; 23(16 suppl):745s (Abstract 8067).
45. Gralla RJ, Hollen PJ, Leighl NB, et al. The Feasibilty of Converting the Paper Lung Cancer Symptom Scale into a Computer-Assisted Quality of Life Instrument (LCSS-QL): Prospective Evaluation of the Attitudes of Patients, Physicians and Nurses in a Non-Small Cell Lung Cancer Trial. ISOQOL 2007. Presented at: ISO-QOL Conference on Patient Reported Outcomes in Clinical Practice, June 24-26, 2007. Abstract 1212.
46. Davis K, Yount S, Del Ciello K, et al. An innovative symptom monitoring tool for people with advanced lung cancer: a pilot demonstration. J Support Oncol 2007; 5:381-7.
47. Cayuela D, Vidal ML, Gil M, et al. Validation of a digital electronic device for the measuring of quality of life in patients diagnosed with advanced lung cancer and che-motherapeutic treatment during the day in oncological surgery. Clin Transl Oncol 2007; 9:176-7 (Abstract P-297).